ARTICLE | Clinical News
TOBI tobramycin solution for inhalation: Phase II; marketed to treat P. aeruginosa infection in patients with cystic fibrosis (CF)
August 28, 2000 7:00 AM UTC
PGNS published in the American Journal of Respiratory and Critical Care Medicine data from its previously reported 74-patient Phase II trial (see BioCentury, May 3, 1999). Following inhalation of 300 mg TOBI twice per day for 4 weeks, bacterial levels decreased more than 99.999 percent compared to no change with placebo, and 2 weeks after stopping therapy, 35 percent of treated patients showed eradication of P. aeruginosa in the sputum compared to none in the placebo group. ...